Selective COX-2 Inhibitors and Risk of Myocardial Infarction

Journal of Vascular Research - Tập 42 Số 4 - Trang 312-324 - 2005
Florian Krötz1, Thomas M. Schiele1, Volker Klauß1, Hae‐Young Sohn1
1Cardiology and

Tóm tắt

Selective inhibitors of cyclooxygenase-2 (COX-2, ‘coxibs’) are highly effective anti-inflammatory and analgesic drugs that exert their action by preventing the formation of prostanoids. Recently some coxibs, which were designed to exploit the advantageous effects of non-steroidal anti-inflammatory drugs while evading their side effects, have been reported to increase the risk of myo cardial infarction and atherothrombotic events. This has led to the withdrawal of rofecoxib from global markets, and warnings have been issued by drug authorities about similar events during the use of celecoxib or valdecoxib/parecoxib, bringing about questions of an inherent atherothrombotic risk of all coxibs and consequences that should be drawn by health care professionals. These questions need to be addressed in light of the known effects of selective inhibition of COX-2 on the cardiovascular system. Although COX-2, in contrast to the cyclooxygenase-1 (COX-1) isoform, is regarded as an inducible enzyme that only has a role in pathophysiological processes like pain and inflammation, experimental and clinical studies have shown that COX-2 is constitutively expressed in tissues like the kidney or vascular endothelium, where it executes important physiological functions. COX-2-dependent formation of prostanoids not only results in the mediation of pain or inflammatory signals but also in the maintenance of vascular integrity. Especially prostacyclin (PGI<sub>2</sub>), which exerts vasodilatory and antiplatelet properties, is formed to a significant extent by COX-2, and its levels are reduced to less than half of normal when COX-2 is inhibited. This review outlines the rationale for the development of selective COX-2 inhibitors and the pathophysiological consequences of selective inhibition of COX-2 with special regard to vasoactive prostaglandins. It describes coxibs that are current ly available, evaluates the current knowledge on the risk of atherothrombotic events associated with their intake and critically discusses the consequences that should be drawn from these insights.

Từ khóa


Tài liệu tham khảo

10.1056%2FNEJMp048286

10.1136%2Fbmj.323.7316.767

10.1016%2Fj.atherosclerosis.2004.10.001

10.1096%2Ffj.03-0645rev

10.1016/j.bbamcr.2003.08.003

10.1038%2Fnrd1225

10.1146%2Fannurev.biochem.69.1.145

10.1073%2Fpnas.162468699

10.1016%2FS0140-6736%2803%2912841-3

10.1016%2Fj.plefa.2003.04.002

10.1016%2F0002-9149%2891%2990379-Y

10.1016%2FS0163-7258%2896%2900103-9

10.1378%2Fchest.119.1_suppl.39S

10.1172%2FJCI200113418

10.1002%2F1529-0131%28200008%2943%3A8%3C1891%3A%3AAID-ANR28%3E3.0.CO%3B2-R

10.1161%2F01.CIR.0000124715.27937.78

10.4065%2F75.10.1027

10.1006%2Fbbrc.2000.3885

10.1124%2Fjpet.300.2.367

10.1007%2FBF00398975

10.1016%2FS0014-5793%2899%2901088-1

10.1677%2Fjme.0.0160107

10.1093%2Fmolehr%2F5.9.880

10.1677%2Fjme.0.0220125

10.1006%2Fexer.2001.0977

10.1016%2FS0006-2952%2802%2901422-3

10.1046%2Fj.1365-2141.2003.04247.x

10.1074%2Fjbc.275.20.15314

10.1016%2FS0149-2918%2899%2980016-2

10.1002%2F1529-0131%28200005%2943%3A5%3C978%3A%3AAID-ANR4%3E3.0.CO%3B2-0

10.1002%2F1529-0131%28199809%2941%3A9%3C1591%3A%3AAID-ART9%3E3.0.CO%3B2-J

10.1056%2FNEJM200011233432103

10.1016%2FS0140-6736%2803%2912560-3

10.1080%2F03009740310004766

10.2165%2F00003495-200464190-00008

10.1177%2F0091270003043005005

10.1053%2Fajem.2002.32635

10.1592%2Fphco.21.15.1223.33891

10.1161%2F01.ATV.0000116219.09040.8c

10.1016%2FS0140-6736%2804%2916893-1

10.1097%2F00042737-200210000-00011

10.1111%2Fj.1572-0241.2003.07598.x

10.1073%2Fpnas.96.1.272

10.1161%2F01.CIR.0000143234.51796.A9

10.1016%2Fj.jacc.2003.09.041

10.1161%2F01.CIR.0000104565.78013.AD

10.1172%2FJCI200214752

10.1172%2FJCI9523

10.1161%2F01.HYP.0000084603.93510.28

10.1161%2F01.CIR.0000145613.01188.0B

10.1161%2F01.CIR.0000014927.74465.7F

10.1038%2Fsj.bjp.0703632

10.1161%2F01.CIR.0000051361.69808.3A

10.1161%2F01.CIR.0000139338.12464.5F

10.1016%2Fj.jacc.2003.05.006

10.1016%2FS0008-6363%2803%2900464-4

10.1152%2Fajpheart.01176.2003

10.1126%2Fscience.1103333

10.1161%2F01.HYP.0000156879.83448.93

10.1016/j.bbamcr.2005.10.002

10.1161%2F01.CIR.0000132491.96623.04

10.1001%2Farchinte.163.4.481

10.1056%2FNEJMoa050493

10.1016%2FS0140-6736%2804%2917514-4

10.1161%2F01.CIR.0000127578.21885.3E

10.1056%2FNEJMoa050405

10.1016%2FS0002-9149%2803%2900659-3

10.1016%2FS0002-9149%2802%2902234-8

10.1016%2FS0022-5223%2803%2900125-9

10.1056%2FNEJMoa050330

10.1097%2F01.mjt.0000127360.23508.04

10.1016%2FS0140-6736%2804%2916894-3

10.1080%2F03009740410005728

10.1517%2F14740338.3.6.607

10.1345%2Faph.1D296

10.1016%2Fj.coph.2003.12.003

10.1161%2F01.RES.0000153150.27690.f2

10.1016%2Fj.amjmed.2003.09.050